Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapy.
Uri KopylovJurij HanzelClaire LiefferinckxDavide De MarcoNicola ImperatoreNikolas PlevrisIria Baston-ReyRichard J HarrisMarie TruyensViktor DomislovicStephan VavrickaVince B C BiemansSally MyersShaji SebastianShomron Ben-HorinYago González LamaCyrielle GillettaBar-Gil Shitrit AriellaZuzana ZelinkovaRoni WeisshofDarragh StoranEran ZittanKlaudia FarkasTamas MolnarDenis FranchimontAnneline CremerWaqqas AfifFabiana CastiglioneCharles LeesManuel Barreiro-de AcostaTriana LobatonGlen DohertyZeljko KrznaricMarieke PierikFrank HoentjenDavid DrobnePublished in: Alimentary pharmacology & therapeutics (2020)
Intensification of ustekinumab maintenance dosage was effective in over 50% of the patients. This strategy should be considered in patients who are nonresponsive to every 8 weeks ustekinumab maintenance dosing.